Skip to main navigation Skip to search Skip to main content

Clinical features and survival outcomes of invasive aspergillosis in pediatric patients at a medical school in Thailand

  • Suvaporn Anugulruengkitt
  • , Panruethai Trinavarat
  • , Punchavit Chantranuwat
  • , Suchada Sritippayawan
  • , Chitsanu Pancharoen
  • , Thanyawee Puthanakit
  • Chulalongkorn University

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Background: Invasive aspergillosis (IA) is a severe infection in immunocompromised patients. Recently, serum galactomannan has been widely used for diagnosis and voriconazole as an antifungal agent. The objective of this study is to describe clinical features and survival outcomes of IA. Material and Method: A retrospective chart review of IA in patients younger than 18 years old at King Chulalongkorn Memorial Hospital, Thailand, was conducted. Clinical definitions were based on criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) 2008. Results: Between January 2006 and December 2012, 40 cases of invasive aspergillosis were identified, classified as proven (8 patients, 20%), probable (28, 70%), and possible IA (4, 10%). Median age of patients was 10 years (range, 42 days-17 years). The most common underlying disease was hematologic malignancy (60%). The major risk factor was neutropenia (65%) with median duration of 21 days (range, 4-58 days). The most common site of infection was in the lungs (80%). The most common computed tomography chest finding was nodules (71%). An air crescent sign was seen only in 11% and a halo sign was found only in 7% of patients. Serum galactomannan was positive in 78% of patients with median value of 1.34 (range 0.5-5.6). Only seven patients (17%) had microbiological confirmation, of which were Aspergillus flavus (4 cases) and Aspergillus fumigates (3 cases). Antifungal therapy included voriconazole (23 patients, 58%), amphotericin B (12, 30%), liposomal amphotericin B (3, 8%), caspofungin (1, 2%) and itraconazole (1, 2%). Two deaths related to angioinvasive complications of aspergillosis (pulmonary hemorrhage and rupture mycotic aneurysm) were reported. The 3-month and 12- month survival rates after diagnosed IA were 73.7% and 56.7%, respectively. The major cause of death was new episode of sepsis found in 11 cases (52%). Conclusion: The 1-year survival rate was poor; however, cause of death is related to complications of the immunocompromised state not from IA.

Original languageEnglish
Pages (from-to)150-158
Number of pages9
JournalJournal of the Medical Association of Thailand
Volume99
Issue number2
Publication statusPublished - Feb 2016
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antifungal therapy
  • Invasive aspergillosis
  • Treatment outcome

Fingerprint

Dive into the research topics of 'Clinical features and survival outcomes of invasive aspergillosis in pediatric patients at a medical school in Thailand'. Together they form a unique fingerprint.

Cite this